The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were look­ing for more ev­i­dence of just how im­por­tant Am­gen’s patent win on En­brel is for the com­pa­ny and its in­vestors, Eval­u­atePhar­ma has come up with a for­ward-look­ing con­sen­sus es­ti­mate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.